Similar articles for PMID: 26832420

Year	Number of Results
2006	1
2007	10
2008	8
2009	13
2010	11
2011	9
2012	14
2013	11
2014	13
2015	11
2016	12
2017	6
2018	1
2020	1
2021	1
2024	0

1

[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].

Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F. Bretagne M, et al. Bull Cancer. 2016 Mar;103(3):259-72. doi: 10.1016/j.bulcan.2015.10.020. Epub 2016 Jan 29. Bull Cancer. 2016. PMID: 26832420 Review. French.

2

[Oral drugs inhibiting the VEGF pathway].

Ropert S, Mir O, Armand JP. Ropert S, et al. Bull Cancer. 2007 Jul;94 Spec No:S180-90. Bull Cancer. 2007. PMID: 17846003 Review. French.

3

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Abdel-Rahman O, Fouad M. Abdel-Rahman O, et al. Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207. doi: 10.1016/j.critrevonc.2014.06.003. Epub 2014 Jul 1. Crit Rev Oncol Hematol. 2014. PMID: 25028151 Review.

4

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.

Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T. Daimon M, et al. Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076. Epub 2012 May 23. Jpn J Clin Oncol. 2012. PMID: 22628612

5

Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.

Takada M, Yasui T, Oka T, Shioyama W, Kuroda T, Nakai Y, Nishimura K, Mukai M, Fujita M. Takada M, et al. Int Heart J. 2018 Sep 26;59(5):1174-1179. doi: 10.1536/ihj.17-461. Epub 2018 Aug 29. Int Heart J. 2018. PMID: 30158382 Free article.

6

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Rini BI, et al. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.

7

[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

Török S, Döme B. Török S, et al. Magy Onkol. 2012 Mar;56(1):3-15. Epub 2012 Jan 3. Magy Onkol. 2012. PMID: 22403757 Free article. Review. Hungarian.

8

[Dermatologic side effects induced by new angiogenesis inhibitors].

Sibaud V, Garrido-Stowhas I, Cottura E, Chevreau C. Sibaud V, et al. Bull Cancer. 2011 Oct;98(10):1221-9. doi: 10.1684/bdc.2011.1457. Bull Cancer. 2011. PMID: 22001771 Free article. Review. French.

9

[Cutaneous side effects of sorafenib and sunitinib].

Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Autier J, et al. Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Ann Dermatol Venereol. 2008. PMID: 18342102 Review. French. No abstract available.

10

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Cabebe E, Wakelee H. Cabebe E, et al. Curr Treat Options Oncol. 2007 Feb;8(1):15-27. doi: 10.1007/s11864-007-0022-4. Curr Treat Options Oncol. 2007. PMID: 17634832 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year